O	0	3	The
O	4	15	association
O	16	23	between
O	24	33	adherence
O	34	38	with
B-intervention	39	43	oral
I-intervention	44	59	bisphosphonates
O	60	63	and
O	64	67	the
O	68	72	risk
O	73	75	of
O	76	82	breast
O	83	89	cancer
O	90	92	in
O	93	97	post
O	97	98	-
O	98	108	menopausal
O	109	114	women
O	114	115	.

O	116	123	Several
O	124	137	observational
O	138	145	studies
O	146	150	have
O	151	160	suggested
O	161	162	a
O	163	173	protective
O	174	180	effect
O	181	183	of
O	184	188	oral
O	189	204	bisphosphonates
O	205	206	(
O	206	208	BP
O	208	209	)
O	210	212	on
O	213	216	the
O	217	221	risk
O	222	224	of
O	225	231	breast
O	232	238	cancer
O	238	239	,
O	240	243	but
O	244	246	no
O	247	251	such
O	252	263	association
O	264	267	has
O	268	272	been
O	273	277	seen
O	278	280	in
O	281	291	randomized
O	292	299	control
O	300	306	trials
O	306	307	.

O	308	311	The
O	312	316	role
O	317	319	of
O	320	324	oral
O	325	327	BP
O	328	330	in
O	331	337	breast
O	338	344	cancer
O	345	355	prevention
O	356	363	remains
O	364	371	unclear
O	371	372	.

O	373	375	To
O	376	387	investigate
O	388	391	the
O	392	403	association
O	404	411	between
O	412	421	different
O	422	428	levels
O	429	431	of
O	432	434	BP
O	435	443	exposure
O	444	447	and
O	448	454	breast
O	455	461	cancer
O	462	471	incidence
O	472	474	in
O	475	476	a
O	477	483	cohort
O	484	486	of
O	487	499	osteoporotic
O	500	504	post
O	504	505	-
O	505	515	menopausal
O	516	521	women
O	521	522	.

O	523	527	This
O	528	538	historical
O	539	550	prospective
O	551	556	study
O	557	560	was
O	561	570	conducted
O	571	576	using
O	577	580	the
O	581	593	computerized
O	594	603	databases
O	604	606	of
O	607	614	Maccabi
O	615	625	Healthcare
O	626	634	Services
O	635	636	(
O	636	639	MHS
O	639	640	)
O	641	643	in
B-location	644	650	Israel
O	650	651	.

O	652	660	Included
O	661	663	in
O	664	667	the
O	668	673	study
O	674	678	were
B-eligibility	679	689	osteopenic
I-eligibility	690	693	and
I-eligibility	694	706	osteoporotic
I-eligibility	707	712	women
O	713	717	aged
B-age	718	720	55
I-age	720	721	-
I-age	721	723	75
I-age	724	729	years
B-eligibility	730	733	who
I-eligibility	734	741	started
I-eligibility	742	744	BP
I-eligibility	745	752	therapy
I-eligibility	753	760	between
I-eligibility	761	765	1998
I-eligibility	766	769	and
I-eligibility	770	774	2012
O	774	775	.

O	776	779	The
O	780	788	subjects
O	789	793	were
O	794	802	enrolled
O	803	805	in
O	806	809	MHS
O	810	813	for
O	814	816	at
O	817	822	least
O	823	824	3
O	825	830	years
O	831	837	before
O	838	845	therapy
O	846	856	initiation
O	856	857	,
O	858	861	and
O	862	865	had
O	866	867	a
O	868	875	minimum
O	876	882	follow
O	882	883	-
O	883	885	up
O	886	888	of
O	889	890	5
O	891	896	years
O	897	899	in
O	900	903	MHS
O	903	904	.

O	905	910	Women
O	911	915	with
O	916	917	a
O	918	926	previous
O	927	933	cancer
O	933	934	,
O	935	938	and
O	939	944	women
O	945	952	treated
O	953	957	with
O	958	967	selective
O	968	976	estrogen
O	977	985	receptor
O	986	996	modulators
O	997	998	(
O	998	1003	SERMs
O	1003	1004	)
O	1005	1009	were
O	1010	1018	excluded
O	1018	1019	.

O	1020	1022	BP
O	1023	1031	exposure
O	1032	1035	was
O	1036	1045	expressed
O	1046	1048	in
O	1049	1058	quintiles
O	1059	1061	of
O	1062	1072	proportion
O	1073	1075	of
O	1076	1080	days
O	1081	1088	covered
O	1089	1090	(
O	1090	1093	PDC
O	1093	1094	)
O	1095	1099	with
O	1100	1102	BP
O	1103	1109	during
O	1110	1116	follow
O	1116	1117	-
O	1117	1119	up
O	1120	1126	period
O	1127	1130	and
O	1131	1137	cancer
O	1138	1147	incidence
O	1148	1151	was
O	1152	1163	ascertained
O	1164	1166	by
O	1167	1170	the
O	1171	1177	Israel
O	1178	1186	National
O	1187	1192	Tumor
O	1193	1201	Registry
O	1201	1202	.

O	1203	1209	Person
O	1209	1210	-
O	1210	1215	years
O	1216	1218	of
O	1219	1225	follow
O	1225	1226	-
O	1226	1228	up
O	1229	1234	began
O	1235	1237	on
O	1238	1245	January
O	1246	1249	1st
O	1249	1250	,
O	1251	1255	1998
O	1256	1259	and
O	1260	1265	ended
O	1266	1268	at
O	1269	1272	the
O	1273	1277	date
O	1278	1280	of
O	1281	1287	cancer
O	1288	1297	diagnosis
O	1297	1298	,
O	1299	1304	death
O	1304	1305	,
O	1306	1308	or
O	1309	1317	December
O	1318	1322	31st
O	1322	1323	,
O	1324	1328	2012
O	1328	1329	,
O	1330	1339	whichever
O	1340	1348	occurred
O	1349	1354	first
O	1354	1355	.

O	1356	1357	A
O	1358	1363	total
O	1364	1366	of
B-total-participants	1367	1369	11
I-total-participants	1369	1370	,
I-total-participants	1370	1373	717
O	1374	1382	patients
O	1383	1384	(
B-age	1384	1388	mean
I-age	1389	1392	age
I-age	1393	1394	=
I-age	1395	1397	66
I-age	1397	1398	.
I-age	1398	1400	87
I-age	1401	1402	Â±
I-age	1403	1404	4
I-age	1404	1405	.
I-age	1405	1407	38
O	1407	1408	)
O	1409	1413	were
O	1414	1422	eligible
O	1423	1426	for
O	1427	1430	the
O	1431	1439	analysis
O	1439	1440	.

O	1441	1447	During
O	1448	1449	a
O	1450	1455	total
O	1456	1458	of
O	1459	1462	130
O	1462	1463	,
O	1463	1466	252
O	1467	1473	person
O	1473	1474	-
O	1474	1479	years
O	1480	1482	of
O	1483	1489	follow
O	1489	1490	-
O	1490	1492	up
O	1492	1493	,
O	1494	1495	(
O	1495	1499	mean
O	1500	1501	7
O	1501	1502	.
O	1502	1503	2
O	1504	1509	years
O	1509	1510	)
O	1511	1514	173
B-outcome	1515	1523	incident
I-outcome	1524	1529	cases
I-outcome	1530	1532	of
I-outcome	1533	1539	breast
I-outcome	1540	1546	cancer
O	1547	1551	were
O	1552	1561	diagnosed
O	1561	1562	.

O	1563	1571	Compared
O	1572	1574	to
O	1575	1580	women
O	1581	1585	with
O	1586	1587	a
O	1588	1591	PDC
O	1592	1596	with
O	1597	1599	BP
O	1600	1602	of
O	1603	1605	20
O	1605	1606	%
O	1607	1609	or
O	1610	1615	lower
O	1615	1616	,
O	1617	1620	the
B-outcome	1621	1629	adjusted
I-outcome	1630	1636	hazard
I-outcome	1637	1642	ratio
I-outcome	1643	1646	for
I-outcome	1647	1653	breast
I-outcome	1654	1660	cancer
O	1661	1665	were
O	1666	1668	HR
O	1669	1670	=
O	1671	1672	0
O	1672	1673	.
O	1673	1675	81
O	1676	1677	(
O	1677	1679	95
O	1679	1680	%
O	1680	1682	CI
O	1682	1683	:
O	1684	1685	0
O	1685	1686	.
O	1686	1688	48
O	1688	1689	-
O	1689	1690	1
O	1690	1691	.
O	1691	1693	39
O	1693	1694	)
O	1694	1695	,
O	1696	1698	HR
O	1699	1700	=
O	1701	1702	0
O	1702	1703	.
O	1703	1705	82
O	1706	1707	(
O	1707	1709	95
O	1709	1710	%
O	1710	1712	CI
O	1712	1713	:
O	1714	1715	0
O	1715	1716	.
O	1716	1718	50
O	1718	1719	-
O	1719	1720	1
O	1720	1721	.
O	1721	1723	33
O	1723	1724	)
O	1724	1725	,
O	1726	1728	HR
O	1729	1730	=
O	1731	1732	0
O	1732	1733	.
O	1733	1735	72
O	1736	1737	(
O	1737	1739	95
O	1739	1740	%
O	1740	1742	CI
O	1742	1743	:
O	1743	1744	0
O	1744	1745	.
O	1745	1747	45
O	1747	1748	-
O	1748	1749	1
O	1749	1750	.
O	1750	1752	15
O	1752	1753	)
O	1754	1757	and
O	1758	1760	HR
O	1761	1762	=
O	1763	1764	1
O	1764	1765	.
O	1765	1767	14
O	1768	1769	(
O	1769	1771	95
O	1771	1772	%
O	1772	1774	CI
O	1774	1775	:
O	1775	1776	0
O	1776	1777	.
O	1777	1779	76
O	1779	1780	-
O	1780	1781	1
O	1781	1782	.
O	1782	1784	70
O	1784	1785	)
O	1786	1791	among
O	1792	1797	women
O	1798	1802	with
O	1803	1805	20
O	1805	1806	-
O	1806	1808	40
O	1808	1809	%
O	1809	1810	,
O	1811	1813	40
O	1813	1814	-
O	1814	1816	60
O	1816	1817	%
O	1817	1818	,
O	1819	1821	60
O	1821	1822	%
O	1822	1823	-
O	1823	1825	80
O	1825	1826	%
O	1826	1827	,
O	1828	1831	and
O	1832	1834	80
O	1834	1835	%
O	1836	1838	or
O	1839	1845	higher
O	1845	1846	,
O	1847	1850	PDC
O	1850	1851	,
O	1852	1864	respectively
O	1864	1865	.

O	1866	1868	In
O	1869	1873	this
O	1874	1879	study
O	1879	1880	,
O	1881	1883	we
O	1884	1887	did
O	1888	1891	not
O	1892	1896	find
O	1897	1898	a
O	1899	1910	significant
O	1911	1922	association
O	1923	1930	between
O	1931	1935	oral
O	1936	1938	BP
O	1939	1946	therapy
O	1947	1950	for
O	1951	1963	osteoporosis
O	1964	1967	and
O	1968	1971	the
O	1972	1976	risk
O	1977	1979	of
O	1980	1986	breast
O	1987	1993	cancer
O	1994	1996	in
O	1997	2011	postmenopausal
O	2012	2017	women
O	2017	2018	.

O	2019	2022	The
O	2023	2034	discrepancy
O	2035	2042	between
O	2043	2046	our
O	2047	2054	results
O	2055	2058	and
O	2059	2062	the
O	2063	2070	reports
O	2071	2073	of
O	2074	2078	such
O	2079	2081	an
O	2082	2093	association
O	2094	2096	in
O	2097	2110	observational
O	2111	2118	studies
O	2119	2124	might
O	2125	2134	originate
O	2135	2139	from
O	2140	2142	an
O	2143	2153	indication
O	2154	2158	bias
O	2158	2159	.
